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Background
Endothelial cells, like gate-keepers of the vascular bed,
can actively protect against the inflammatory process.
Prostaglandin E2 (PGE2) could be one of the mediators
that can promote the barrier function of endothelial
cells. PGE2 exerts its cellular effects by binding to four
different E-prostanoid receptors (EP1–4)t h a tb e l o n gt o
the family of G protein-coupled receptors. This project
aimed at characterizing the barrier-protective properties
of PGE2 and especially EP4 receptor on human pulmon-
ary microvascular endothelial cells (HMVEC-L).
Methods
The endothelial barrier properties were analyzed by mea-
surements of transendothelial electrical resistance
(TEER) by Endohm and by ECIS (Electric Cell substrate
Impedance Sensing) devices. Morphological studies were
performed with immunofluorescence microscopy. Differ-
ent protein expressions were detected by flow cytometry.
Leukocyte diapedesis was studied by performing transen-
dothelial migration assays of neutrophils and eosinophils.
Results
We found that the EP4 receptor is expressed on HMVEC-
L. PGE2 and the selective EP4 receptor agonist (ONO-AE1-
329) prevented the barrier-disrupting effect of thrombin on
the endothelial monolayer, as it was visualized by VE-
cadherin staining. Selective blocking of EP4 receptors (EP4
antagonist ONO-AE3-208) inhibited the protective effect of
PGE2 on endothelial monolayers. PGE2 and the EP4 agonist
enhanced the regeneration of electrically wounded
endothelial monolayers. The specificity of EP4 receptor
involvement was proven by using the EP4 receptor antago-
nist and selective agonists for EP2 and EP3 receptors. PGE2
and the EP4 receptor agonist attenuated the TNF-a-
induced up-regulation of E-selectin. Surprisingly, this effect
was not affected by an adenylyl cyclase inhibitor, but inhibi-
tion of PKC activity reversed the effect of the EP4 receptor
agonist and PGE2 at reducing the E-selectin expression. In
the cell interaction assays, thrombin or TNF-a increased
the permeability of endothelial monolayers which also
enhanced the transmigration of neutrophils and eosino-
phils, respectively. These effects were prevented by the
selective activation of EP4 receptors.
Conclusions
Our data support the hypothesis that endothelial cells,
as gate-keepers of the vessel wall can actively participate
in the inflammatory process. We have shown that PGE2,
via activating EP4 receptors, enhances the barrier func-
tion of the endothelium by protecting the endothelial
adherent junctional network and preventing leukocyte
diapedesis. Therefore, EP4 agonists might be promising
new therapeutic tools in treating inflammatory diseases.
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